Business Standard

Tuesday, December 24, 2024 | 09:59 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

10 years of pharmaceutical sector: Controls, regulations stymie growth

It has also been a decade of major mergers and acquisitions, the most noteworthy one perhaps being the Sun Pharma-Ranbaxy deal

Approval for generics drug up but US business shrinks for home firms
Premium

Sohini Das Ahmedabad
The past 10 years have been eventful for pharma. The domestic market has grown to Rs 1.1 trillion from Rs 363 billion in 2008. There have been 97,240 brand launches, and exports, led by the US market, almost doubled from $8.7 billion in 2008-09 to $16.88 billion in 2016-17.

It has also been a decade of major mergers and acquisitions, the most noteworthy one perhaps being the Sun Pharma-Ranbaxy deal and the epic hostile acquisition of Israel’s Taro by Sun Pharma.

An industry veteran who was at the helm of a leading pharmaceutical company in India says these are two

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in